Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTYR Pharma director Sara Zaknoen received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and were awarded with no purchase price at grant. They vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. After this award, she holds options for 50,000 shares directly.
aTYR Pharma reported that director Paul Schimmel received a grant of stock options as part of the company’s non-employee director compensation policy. The award covers 50,000 options to buy common stock at an exercise price of $0.95 per share, expiring on May 11, 2036.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 annual stockholders’ meeting, conditioned on his continued board service. Following this grant, Schimmel holds 50,000 stock options directly, and the filing does not show additional derivative holdings.
aTyr Pharma reported preliminary cash, cash equivalents, restricted cash and available-for-sale investments of $68.3 million as of March 31, 2026, and outlined a new pivotal plan for its lead drug efzofitimod in pulmonary sarcoidosis.
Following a Type C meeting with the FDA, the company plans a new global Phase 3 trial in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease, using change in forced vital capacity (FVC) at week 48 as the primary endpoint and the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.
The 54-week study is expected to enroll about 372 patients on stable low-dose steroids and/or immunosuppressants, with efzofitimod 5.0 mg/kg or placebo given intravenously every three weeks for 17 doses. aTyr intends to file an IND for this C-006 study in June 2026, incorporating enhanced safety monitoring and risk mitigation measures.
aTyr Pharma Inc amendment: The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned and 0% of the common stock as of the amendment. The filing states Vanguard undertook an internal realignment on January 12, 2026 and, in accordance with SEC Release No. 34-39538, certain subsidiaries will report separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, with an execution date of 03/26/2026. The submission lists Vanguard's principal address in Malvern, Pennsylvania.
aTyr Pharma, Inc. is asking stockholders to vote at its 2026 annual meeting on several key items. Stockholders will elect three Class II directors to terms ending at the 2029 annual meeting, ratify Ernst & Young LLP as auditor for the year ending December 31, 2026, and cast an advisory “say‑on‑pay” vote on compensation for named executive officers.
The company seeks approval of an amendment to its 2015 Stock Option and Incentive Plan to add 4,000,000 shares, bringing the maximum shares reserved under the plan to 19,725,101 and extending the incentive stock option grant period through February 20, 2036. Stockholders are also asked to approve an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 170,000,000 to 340,000,000 shares. The record date for voting is March 16, 2026, when 98,051,212 shares of common stock were outstanding and entitled to vote.
aTyr Pharma is soliciting proxies for its 2026 Annual Meeting to be held May 11, 2026 at its San Diego headquarters. Stockholders will vote to elect three Class II directors, ratify Ernst & Young LLP as auditor, and cast an advisory vote on named executive officer compensation.
The meeting also seeks approval to increase authorized common stock from 170,000,000 to 340,000,000 shares and to increase the 2015 Stock Option and Incentive Plan by 4,000,000 shares (to 19,725,101). Proposals 2 and 5 are designated routine for broker voting; Proposals 1, 3 and 4 are designated non-routine. The company will mail a Notice of Internet Availability of Proxy Materials and will reimburse brokers; proxy solicitation advisor Alliance Advisors’ fee is not expected to exceed $17,000.
aTyr Pharma is a clinical-stage biotechnology company developing therapies for fibrosis and inflammation based on extracellular tRNA synthetase biology. Its lead drug, efzofitimod, targets interstitial lung diseases such as pulmonary sarcoidosis and systemic sclerosis-associated ILD.
A global Phase 3 sarcoidosis trial (EFZO-FIT) did not meet its primary endpoint of reducing oral steroid use versus placebo, but showed nominal improvements in quality-of-life measures and fatigue, with stable lung function and a generally favorable safety profile. The company plans a Type C FDA meeting in April 2026 to discuss a regulatory path.
aTyr is also running the EFZO-CONNECT Phase 2 trial in SSc-ILD, has an orphan/Fast Track regulatory portfolio, and a discovery platform with preclinical candidates ATYR0101 and ATYR0750 for fibrotic and inflammatory diseases. It remains pre-commercial, has a Japanese partnership with Kyorin, and highlights significant ongoing losses, funding needs and clinical, regulatory and market risks.
aTyr Pharma reported fourth quarter and full year 2025 results and provided a pipeline update centered on its lead drug efzofitimod for interstitial lung diseases.
The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint of reducing mean daily oral corticosteroid dose at week 48, but the 5.0 mg/kg dose showed clinical benefits on several pre-specified measures of symptoms and quality of life, and maintained lung function with a favorable safety profile. The company has a Type C meeting with the FDA scheduled for mid-April 2026 to review the data and determine the regulatory path forward.
aTyr’s Phase 2 EFZO-CONNECT trial in systemic sclerosis-related interstitial lung disease is on track to complete enrollment in the first half of 2026. The company also highlighted preclinical progress for ATYR0101 in fibrosis and published research on a bispecific NRP2/PLXNA1 antibody with potential anticancer activity. For 2025, aTyr generated $190 thousand in collaboration revenue, incurred $60.2 million in research and development expenses and $17.6 million in general and administrative expenses, leading to a net loss attributable to aTyr of $74.1 million, or $0.80 per share. Cash, cash equivalents, restricted cash and investments totaled $80.9 million as of December 31, 2025.
aTyr Pharma President and CEO Sanjay Shukla reported routine equity compensation activity. On February 3, 2026, 10,375 restricted stock units granted on February 3, 2022 vested and converted into the same number of common shares on a one-for-one basis.
On February 4, 2026, he sold 3,745 common shares at $0.976 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, Shukla directly owned 153,553 shares of aTyr Pharma common stock. The RSU award vests in four equal annual installments from February 3, 2023 through February 3, 2026 and can vest earlier if he is terminated without cause following a change of control.